JPS63101334A - 持続放出型医薬組成物 - Google Patents
持続放出型医薬組成物Info
- Publication number
- JPS63101334A JPS63101334A JP62256149A JP25614987A JPS63101334A JP S63101334 A JPS63101334 A JP S63101334A JP 62256149 A JP62256149 A JP 62256149A JP 25614987 A JP25614987 A JP 25614987A JP S63101334 A JPS63101334 A JP S63101334A
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- hydroxypropyl methylcellulose
- microcrystalline cellulose
- acetylsalicylic acid
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 44
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 50
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 36
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 26
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 23
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 23
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 23
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 23
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 22
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 22
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 22
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 22
- 239000013543 active substance Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 18
- 229960004889 salicylic acid Drugs 0.000 claims description 18
- 229920000881 Modified starch Polymers 0.000 claims description 13
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 150000003839 salts Chemical group 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000005484 gravity Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000013265 extended release Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 5
- 239000012190 activator Substances 0.000 claims 4
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 3
- 239000007891 compressed tablet Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229920003091 Methocel™ Polymers 0.000 claims 1
- 229920002877 acrylic styrene acrylonitrile Polymers 0.000 description 32
- 229940079593 drug Drugs 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 229960001860 salicylate Drugs 0.000 description 9
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 9
- -1 psycholeptics Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229920000945 Amylopectin Polymers 0.000 description 4
- 229920000856 Amylose Polymers 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000010972 statistical evaluation Methods 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940125716 antipyretic agent Drugs 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940058671 bayer aspirin Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940035677 psycholeptics Drugs 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868624213A GB8624213D0 (en) | 1986-10-09 | 1986-10-09 | Sustained release pharmaceutical compositions |
| GB8624213 | 1986-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63101334A true JPS63101334A (ja) | 1988-05-06 |
Family
ID=10605478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62256149A Pending JPS63101334A (ja) | 1986-10-09 | 1987-10-08 | 持続放出型医薬組成物 |
Country Status (24)
| Country | Link |
|---|---|
| JP (1) | JPS63101334A (de) |
| KR (1) | KR880004801A (de) |
| AU (1) | AU7942087A (de) |
| BE (1) | BE1000732A5 (de) |
| CA (1) | CA1332809C (de) |
| CH (1) | CH675831A5 (de) |
| DE (1) | DE3733540A1 (de) |
| DK (1) | DK527487A (de) |
| ES (1) | ES2014518A6 (de) |
| FI (1) | FI874414A (de) |
| FR (1) | FR2604902B1 (de) |
| GB (2) | GB8624213D0 (de) |
| GR (1) | GR871550B (de) |
| HU (1) | HU201875B (de) |
| IL (1) | IL84104A0 (de) |
| IT (1) | IT1221493B (de) |
| LU (1) | LU87009A1 (de) |
| NL (1) | NL8702294A (de) |
| NO (1) | NO874200L (de) |
| NZ (1) | NZ222083A (de) |
| PH (1) | PH24227A (de) |
| PT (1) | PT85880B (de) |
| SE (1) | SE8703889L (de) |
| ZA (1) | ZA877617B (de) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| JP2002541090A (ja) * | 1999-03-31 | 2002-12-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 制御放出製剤中の前糊化澱粉 |
| JP4814885B2 (ja) * | 2004-09-09 | 2011-11-16 | サイコファルマ，エッセ．エ．デ セ．ウヴェ． | ヒドララジン持続放出用医薬組成物および該組成物を含む癌治療薬 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5895663A (en) * | 1997-07-31 | 1999-04-20 | L. Perrigo Company | Pseudoephedrine hydrochloride extended-release tablets |
| US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| SE0102886D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| SE0102888D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| TWI338583B (en) | 2004-05-20 | 2011-03-11 | Otsuka Pharma Co Ltd | Solid pharmaceutical formulation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE795766A (fr) * | 1972-02-22 | 1973-08-22 | Lilly Co Eli | Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4520009A (en) * | 1983-11-28 | 1985-05-28 | Verex Laboratories, Inc. | Sustained released aspirin formulation |
| DE3346571A1 (de) * | 1983-12-23 | 1985-07-04 | Bayer Ag, 5090 Leverkusen | Oral retardierte acetylsalicylsaeureformulierungen |
| WO1985004100A1 (en) * | 1984-03-21 | 1985-09-26 | American Home Products Corporation | Sustained release pharmaceutical capsules |
-
1986
- 1986-10-09 GB GB868624213A patent/GB8624213D0/en active Pending
-
1987
- 1987-09-25 HU HU874311A patent/HU201875B/hu not_active IP Right Cessation
- 1987-09-25 NL NL8702294A patent/NL8702294A/nl not_active Application Discontinuation
- 1987-10-02 CH CH3838/87A patent/CH675831A5/de not_active IP Right Cessation
- 1987-10-02 FR FR878713759A patent/FR2604902B1/fr not_active Expired - Lifetime
- 1987-10-02 BE BE8701131A patent/BE1000732A5/fr not_active IP Right Cessation
- 1987-10-03 DE DE19873733540 patent/DE3733540A1/de not_active Withdrawn
- 1987-10-06 IL IL84104A patent/IL84104A0/xx unknown
- 1987-10-06 LU LU87009A patent/LU87009A1/fr unknown
- 1987-10-06 KR KR870011168A patent/KR880004801A/ko not_active Application Discontinuation
- 1987-10-07 FI FI874414A patent/FI874414A/fi not_active IP Right Cessation
- 1987-10-07 NZ NZ222083A patent/NZ222083A/en unknown
- 1987-10-07 GB GB8723515A patent/GB2195893B/en not_active Expired - Lifetime
- 1987-10-07 AU AU79420/87A patent/AU7942087A/en not_active Abandoned
- 1987-10-07 GR GR871550A patent/GR871550B/el unknown
- 1987-10-07 PT PT85880A patent/PT85880B/pt not_active IP Right Cessation
- 1987-10-07 NO NO874200A patent/NO874200L/no unknown
- 1987-10-08 CA CA000548872A patent/CA1332809C/en not_active Expired - Lifetime
- 1987-10-08 DK DK527487A patent/DK527487A/da not_active Application Discontinuation
- 1987-10-08 IT IT48469/87A patent/IT1221493B/it active
- 1987-10-08 ES ES8702873A patent/ES2014518A6/es not_active Expired - Lifetime
- 1987-10-08 SE SE8703889A patent/SE8703889L/ not_active Application Discontinuation
- 1987-10-08 JP JP62256149A patent/JPS63101334A/ja active Pending
- 1987-10-08 PH PH35906A patent/PH24227A/en unknown
- 1987-10-09 ZA ZA877617A patent/ZA877617B/xx unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| JP2002541090A (ja) * | 1999-03-31 | 2002-12-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 制御放出製剤中の前糊化澱粉 |
| JP4814885B2 (ja) * | 2004-09-09 | 2011-11-16 | サイコファルマ，エッセ．エ．デ セ．ウヴェ． | ヒドララジン持続放出用医薬組成物および該組成物を含む癌治療薬 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1332809C (en) | 1994-11-01 |
| GB8624213D0 (en) | 1986-11-12 |
| BE1000732A5 (fr) | 1989-03-21 |
| AU7942087A (en) | 1988-04-14 |
| PT85880B (pt) | 1990-07-31 |
| DK527487A (da) | 1988-04-10 |
| NO874200D0 (no) | 1987-10-07 |
| GB8723515D0 (en) | 1987-11-11 |
| HUT52958A (en) | 1990-09-28 |
| FI874414A (fi) | 1988-04-10 |
| PH24227A (en) | 1990-05-04 |
| SE8703889D0 (sv) | 1987-10-08 |
| GR871550B (en) | 1988-02-15 |
| NO874200L (no) | 1988-04-11 |
| PT85880A (en) | 1987-11-01 |
| NL8702294A (nl) | 1988-05-02 |
| IT8748469A0 (it) | 1987-10-08 |
| FI874414A0 (fi) | 1987-10-07 |
| HU201875B (en) | 1991-01-28 |
| SE8703889L (sv) | 1988-04-10 |
| GB2195893B (en) | 1991-05-08 |
| FR2604902B1 (fr) | 1991-04-26 |
| ZA877617B (en) | 1989-05-30 |
| FR2604902A1 (fr) | 1988-04-15 |
| LU87009A1 (fr) | 1988-05-03 |
| DE3733540A1 (de) | 1988-04-14 |
| IT1221493B (it) | 1990-07-06 |
| ES2014518A6 (es) | 1990-07-16 |
| CH675831A5 (de) | 1990-11-15 |
| KR880004801A (ko) | 1988-06-27 |
| GB2195893A (en) | 1988-04-20 |
| NZ222083A (en) | 1991-05-28 |
| DK527487D0 (da) | 1987-10-08 |
| IL84104A0 (en) | 1988-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003275855B2 (en) | Sustained-release tramadol formulations with 24-hour efficacy | |
| KR100283709B1 (ko) | 안정한 서방성 경구 투여 조성물 | |
| AU2013274003B2 (en) | Compositions and methods for transmucosal absorption | |
| AU2001260212C1 (en) | Composition | |
| US20170007543A1 (en) | Sustained release of guaifenesin | |
| SE453797B (sv) | Terapeutisk, solid enhetsdoseringsform med forlengt utlosningsmonster vars berarmaterial innehaller hydroxypropylmetylcellulosa med hog molekyler vikt | |
| PT1351668E (pt) | Formas de dosagem farmacêutica de libertação sustida com perfis de dissolução dependentes de ph minimizado | |
| TW508242B (en) | Pharmaceutical composition comprising paracetamol | |
| KR101464771B1 (ko) | 페닐에프린의 지속 방출용 약제학적 조성물 | |
| JP2002326927A (ja) | 塩酸メトホルミン含有速放性錠剤 | |
| AU2009276664B2 (en) | Novel method | |
| CN104812378A (zh) | 固体剂型 | |
| Mohapatra et al. | Formulation, development and evaluation of patient friendly dosage forms of metformin, Part-I: Orally disintegrating tablets | |
| JPS63101334A (ja) | 持続放出型医薬組成物 | |
| TWI326212B (en) | Non-effervescent dosage form intended to be swallowed directly | |
| US7985420B2 (en) | Sustained release of guaifenesin combination drugs | |
| JPH08511009A (ja) | ジクロフェナックを含有する経口固体剤形の製造方法 | |
| AU2014295099A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| JPWO2003075919A1 (ja) | 塩酸ピルジカイニド含有錠剤（乾式） | |
| JP2521463B2 (ja) | 塩酸ジラゼプ持効性錠剤 | |
| Kumar et al. | In vitro and in vivo studies on HPMC-K-100 M matrices containing naproxen sodium | |
| Muthusamy | Formulation and Evaluation of Sustained Release Matrix Tablets of Lamivudine | |
| Singh et al. | Design development and evaluation of matrix tablets of Ambroxol Hydrochloride: In Vitro–In Vivo Study | |
| Patel | Formulation, Development and Evaluation of Expectorant Extended Release Tablet | |
| Nikhate Ram et al. | Design, Development and Evaluation of Metoprolol Succinate Extended Release Tablet |